Advanced searches left 3/3

Acute Promyelocytic Leukemia - Europe PMC

Summarized by Plex Scholar
Last Updated: 04 October 2022

* If you want to update the article please login/register

A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia.

Background Resembling acute promyelocytic leukemia is a special subtype of APL that shares clinical, morphological, and immunophenotypic characteristics with traditional APLs but is not familiar with the PML-RARA fusion gene, and is therefore insensitive to arsenic trioxide and all-trans retinoic acid. Case presentation We described a 25-year-old female patient with a novel fusion gene RARG-HNRNPM via RNA-seq as resembling APL. Patients with RARG-HNRNPM were benefited from a combination chemotherapy homoharringtonine, cytarabine, and aclacinomycin therapy with no relapses. The RARG rearrangement resembling APL is subjected to a variety of factors, including discussion and conclusions. Early in the process, the ATRA/ATO-ATO/AML mixed chemotherapy regimen should be switched to AML mixed chemotherapy regimen.

Source link: https://europepmc.org/article/MED/35544458


AML-372 Acute Promyelocytic Leukemia: A Case of Pseudotumor Cerebri Syndrome During Treatment Consolidation.

Acute promyelocytic leukemia is a subtype of acute myeloid leukemia with distinct morphological, surgical, and genetic features. Pseudotumor cerebri, also known as idiopathic intracranial hypertension, has been described as a neurologic disorder characterized by headache, visual enhancements, papilledema without cerebral mass lesion, venous sinus thromboses, or obstructive hydrocephalus. In APL patients treated with ATRA, the incidence of 'probable'" PTCS is 1. 7%. Case Report: We present here the case of a 20-year-old woman with a BMI of 34. 5 kg/m 2 and ATRA and ATO as induction therapy for a 20-year-old woman with low-/intermediate risk APL. The patient received all of ATRA consolidation therapies as expected, but with a dose cut to 80% of the initial dose and in association with acetazolamide, they were able to receive all of the ATRA consolidation regimens as expected. Conclusions: This case report explores the possibility of pseudotumor cerebri development in young adult patients with APL during consolidation therapy.

Source link: https://europepmc.org/article/MED/36163822


AML-317 Long-Term Follow-Up of Acute Promyelocytic Leukemia: Experience From Clinical Hematology Department of Casablanca.

Context is a magazine that publishes articles about Context Acute promyelocytic leukemia accounts for about 5-10 percent of all AML cases, with a prevalence of about 0. 1 percent. 100,000 is the product of about 0. 1 percent. Patients and methods This is a retrospective descriptive study based on medical records and follow-up of APL patients from 2003 to 2021. The diagnosis was genetically confirmed by locating the PML-RAR fusion gene or demonstrating the t. APL in our department between November 2003 and July 2021. PML-RAR results for 34 patients and karyotyping results for 85 patients were available. Except for 15 patients who died at diagnosis, all 79 patients who were followed up on chemotherapy received chemotherapy: 63 patients were treated with APL protocol and 18 patients Pethema. All three patients died after continuing maintenance therapy, with two cases of neurological relapse and one case of bone marrow relapse.

Source link: https://europepmc.org/article/MED/36163809


AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital.

Context: In newly diagnosed acute promyelocytic leukemia patients, the early death risk and its causes are unclear. Methods We retrospectively evaluated new APL patients treated at MHH between January 2009 and December 2021 using electronic medical records. 5 patients were low-risk, 5 were intermediate-risk, 5 were high-risk, and 15 had high-risk disease by Sanz risk stratification, five patients were low-risk, 5 had intermediate-risk, and 15 had high-risk disease. Sixteen patients had bleeding diathesis, 8 with intracranial hemorrhage, six with gastrointestinal or genitourinary bleeding, and 6 with abdominal wall hematoma; six of them had bleeding diathesis. Patients with high risk disease were given idarubicin or gemtuzumab ozogomicin. Induction of ATRA and arsenic trioxide, twenty-two patients had a CR with ATRA and arsenic trioxide. ED occurred in three patients: 2 within 48 hours of admission and another between days 8 and 15, respectively. Despite 8 patients with ICH, the ED rate in 25 patients was low, despite eight patients presenting with ICH.

Source link: https://europepmc.org/article/MED/36163776


AML-151 Characteristics of Acute Promyelocytic Leukemia Hospitalizations in the United States.

Context In the United States, there is a paucity of recently published population-based studies on acute promyelocytic leukemia. Design Retrospective research using the National Inpatient Sample to identify APL admissions from 2016-2019. According to the standard U. S. population from 2000, the age-adjusted incidence rate for 100,000 U. S. adults was estimated for 100,000 U. S. adults. APL's annual age-adjusted incidence rate of APL in 2016-2019 was 0. 28 percent of 100,000 people, according to the report. Hispanics were the youngest in the country's youngest demographic cohort, with median age of 40 years followed by Blacks & Asian/Pacific Islanders at 47 years and Whites at 56 years. The mean LOS was 7 days higher in teaching hospitals compared to non-teaching hospitals after accounting for confounders. Overall inpatient mortality was 12. 1% and 55. 5 percent deaths within 7 days, with the median time to death being 6 days. The number of early deaths in non-teaching hospitals was higher than late deaths compared to late deaths.

Source link: https://europepmc.org/article/MED/36163774


Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia.

Background: Although autologous hematopoietic cell transplantation is an established treatment for patients with relapsed acute promyelocytic leukemia following recovery to complete remission, the role of allogeneic HCT remains unclear in treating relapsed APL. Objects This study was designed to investigate allogeneic HCT outcomes in patients with relapsed APL, particularly those who were transplanted in non-CR and those who had relapsed after prior autologous HCT. The authors reviewed retrospectively the findings of patients with relapsed APL age u226516 years who underwent allogeneic HCT between 2006 and 2020. According to CR and non-CR, the 5-year OS rates in patients with prior autologous HCT were 47 percent and 6% for those who underwent allogeneic HCT in CR and non-CR. Conclusion Allogeneic HCT still provides a chance for long-term health for those patients with relapsed APL for whom autologous HCT is unlikely to be helpful.

Source link: https://europepmc.org/article/MED/36179987


A Pathogenic NRAS c.38 G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome.

An acute promyelocytic leukemia patient without demonstrating the retinoic acid receptor u03b1 translocation is unusual. abnormal promyelocytes were found with pancytopenia and disseminated intravascular coagulopathy after a year of unusual promyelocytes. Despite residual MDS, this mutation was not present in post-treatment bone marrow aspirate. paraphrasedoutput:. . A mutation could be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia, as seen in the NRAS c. 38 G > A mutation may also be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia.

Source link: https://europepmc.org/article/MED/36130886


Case report: A rare case of acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia.

In several acute myeloid leukemia patients, a retinoic acid receptor gamma gene rearrangement has been observed. AML resembling APL in clinical presentation and experimental results containing a rare cleavage and polyadenylation-specific factor 6 -RARG fusion gene are present here.

Source link: https://europepmc.org/article/MED/36185228


Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia.

Background Although most acute promyelocytic leukemia with low-intermediate risk could survive the induction procedure, early death is still a significant issue in real life, with implications on global survival. HGB 65g/L at diagnosis after induction therapy was a risk factor for early death among low-risk APL patients with low-total risk APL patients. Compared to patients with low risk APL, those with intermediate-risk APL had elevated white blood cell counts, a higher risk of bone marrow promyelocytes, a higher incidence of platelet transfusions during therapy, and more early deaths. The overall health of intermediate-risk APL patients looked worse than those with low-risk APLs.

Source link: https://europepmc.org/article/MED/36185183


Realgar (As 4 S 4 ), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway in vitro .

Acute promyelocytic leukemia is a particular form of acute myelogenous leukemia characterized by the proliferation of abnormal promyelocytes. For more than a hundred years, Traditional Chinese medicine physicians have used realgar to treat APL. The current research sought to determine the effect of realgar on cell death in the APL cell line in vitro and to clarify the underlying mechanism. The cell survival rate, apoptotic assay, morphological changes, ATP levels, and cell cycle arrest were determined in this research, which concluded that after APL cells were treated with different amounts of realgar. Realgar has been shown to significantly reduce APL cell proliferation and cell death in a time- and dose-dependent manner. At the S and G2/M phases, Realgar also induced APL cell cycle arrests. In summary, realgar can cause APL cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway, implying that realgar is an effective anti-APL drug.

Source link: https://europepmc.org/article/MED/36098742

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions